Xcout IntelSign inSubscribe

Repligen Corporation

RGENMedical - Instruments & SuppliesWaltham, MA, United States

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.

Subscribe to see Repligen Corporation’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

Repligen Corporation at a glance

Repligen Corporation is a medical - instruments & supplies company headquartered in Waltham, United States. It is publicly listed (RGEN) with a market capitalisation of $10.7B. Xcout tracks 21 named people at Repligen Corporation, including Olivier Loeillot (President, Chief Executive Officer & Director).

As of 16 November 2026. Source: Xcout Intel.

Industry
Medical - Instruments & Supplies
Headquarters
Waltham, MA, United States
Market cap
$10.7B
Employees
2,000
Ticker
RGEN
Web attention
Top 1M website · rising over 3 months

Repligen Corporation leadership

  • Olivier LoeillotPresident, Chief Executive Officer & Director
  • James R. BylundChief Operating Officer
  • Jason K. GarlandChief Financial Officer & Chief Compliance Officer
  • Brian DouglassSenior VP & Chief Product Officer
  • Heather EmsChief Information Officer
  • Violetta HughesChief Accounting Officer

15 more named people on record for Repligen Corporation, with roles, board committees and tenure — see the full roster →

Recent Repligen Corporation news

12 corporate events on record, with sources — see the full timeline →

Who owns Repligen Corporation

480 institutions reported a position for the quarter ending 30 June 2026.

BlackRock: 9.50%Vanguard: 9.00%Fidelity: 5.90%T. Rowe Price: 5.60%United Capital Financial Advisors: 4.90%Other institutions: 65.10%Repligen Corporat…100.0%held byinstitutions
Ownership of Repligen Corporation by 13F institution and insider
Holder% of shares outstanding
BlackRock9.50%
Vanguard9.00%
Fidelity5.90%
T. Rowe Price5.60%
United Capital Financial Advisors4.90%
Other institutions65.10%
  1. 1BlackRockBlackRock, Inc.9.5%
  2. 2Vanguard7 filers: VANGUARD CAPITAL MANAGEMENT LLC · VANGUARD PORTFOLIO MANAGEMENT LLC · VANGUARD FIDUCIARY TRUST CO · Vanguard Global Advisers, LLC · Vanguard Investments Australia, Ltd. · Vanguard Personalized Indexing Management, LLC · Vanguard National Trust Co9.0%
  3. 3FidelityFMR LLC5.9%
  4. 4T. Rowe Price2 filers: PRICE T ROWE ASSOCIATES INC · T. Rowe Price Investment Management, Inc.5.6%
  5. 5United Capital Financial AdvisorsUNITED CAPITAL FINANCIAL ADVISORS, LLC4.9%

The full list of 480 institutions, with share counts and what each bought or sold since the previous quarter.

Sign in to see it, or subscribe →

Source: SEC Form 13F filings, period ending 30 June 2026; shares outstanding from the company's 10-Q as of 24 July 2026. 13F covers the US-listed holdings of investment managers with more than $100 million under management and is filed up to 45 days after the quarter ends. A firm that files under several names (Vanguard files as two managers) is one row, with its filers listed under it. Insiders and retail holders are in “not held by 13F institutions”.

Repligen Corporation competitors

A few of Repligen Corporation's closest competitors — see the full list of competitors and alternatives →

BioLife Solutions, Inc.BLFS · Medical - Instruments & SuppliesBothell, WA, United States
64% matchPublic

BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa, and other international regions. The company's offerings are essential for various stages of biologic-based therapy development, spanning from foundational and applied research to large-scale commercial manufacturing. Key products include proprietary biopreservation media, such as HypoThermosol FRS and CryoStor, which are engineered to minimize delayed cell damage and death typically associated with preservation. Complementing these are the ThawSTAR products, an automated line of devices for thawing vials and cryobags, designed to precisely manage the heat and timing for optimal biologic material thawing. BLFS also provides innovative cloud-connected evo shipping containers for the passive storage and secure transport of temperature-sensitive biologics and pharmaceuticals. Additionally, its comprehensive range encompasses liquid nitrogen laboratory freezers, various cryogenic equipment and accessories, and specialized storage services for biological and pharmaceutical products. Products are distributed both directly to customers and through a network of third-party distributors. Established in 1987, BioLife Solutions, Inc. maintains its headquarters in Bothell, Washington.

Market cap$1.9B
Employees155
BioLife Solutions, Inc. competitors & alternatives →
Sartorius0NIQ · BiotechGermany
66% matchPublic

Sartorius AG is a global enterprise specializing in comprehensive bioprocess solutions and laboratory products and services. Its extensive portfolio includes advanced analytical instruments such as biosensors, label-free detection systems, SPR technology, live-cell analysis platforms, and flow cytometry apparatus, complemented by a range of cell analysis reagents and consumables. The company manufactures diverse cell culture media tailored for applications spanning antibody and recombinant protein production, viral vaccine development, regenerative medicine, and stem cell research. It also supplies a variety of general media, downstream buffers, microcarriers, strong acids, bases, alcohols, and detergents. Sartorius is a leading provider of bioreactor technologies, offering multi-parallel, benchtop, single-use, stainless steel, cell culture, and microbial models, often integrated with dedicated software applications. A significant portion of its offerings includes a broad array of filtration products: membranes, blotting materials, filter papers, glass and quartz microfibre products, and various filtration devices for ultrafiltration, sterile filtration, harvesting, analytical and diagnostic sample preparation, buffer exchange, particle analysis, pharmaceutical processes, protein/DNA concentration, venting moisture barriers, and clarification. This segment also features syringe filters, buffer and media products, and membrane chromatography solutions. Further expanding its catalog, Sartorius supplies process filtration and chromatography products, fluid management solutions, process analytical technology with data analytics, industrial microbiology systems, water purification units, precision weighing and pipetting/dispensing systems, OEM components, and centrifuges. Beyond products, the company delivers crucial services such as bioprocess development and engineering, protein expression system support, media and process optimization, testing, instrument services, and validation. Serving a wide array of sectors, Sartorius supports life science research, biopharmaceutical manufacturing, quality control and testing, and various applied industries. Established in 1870, this long-standing enterprise maintains its headquarters in Göttingen, Germany.

Market cap$15.7B
Employees14,042
Sartorius competitors & alternatives →
Charles River Laboratories International, Inc.CRL · BiotechWilmington, MA, United States
66% matchPublic

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Market cap$16.3B
Employees18,700
Charles River Laboratories International, Inc. competitors & alternatives →

Get Repligen Corporation's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Something wrong or missing about Repligen Corporation? Suggest a correction · Work at Repligen Corporation? Claim this profile

Is this your company? Add the Xcout Intel badge to your website

Free, for any company on Xcout Intel. It links visitors to this profile.

Repligen Corporation on Xcout Intel

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

Repligen Corporation — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on Repligen Corporation in Xcout Intel

  • 21 named people with titles, LinkedIn and board committees
  • 12 corporate events with sources — deals, leadership changes, layoffs
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →